Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-31

Clinical Trial Update: 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis [Phase 3]

View source ↗

Summary

A 3-year Phase 3 open-label trial evaluating Lorecivivint for knee osteoarthritis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lorecivivint (SM04690)

Snippet

Sponsor: Biosplice Therapeutics, Inc. | Conditions: Osteoarthritis of the Knee | Phase 3 | Status: TERMINATED | Results posted: 2026-03-31